FDA paused public release of pharma rejection letters (CRLs) after a law firm's April citizen petition. Last published CRL was for AbbVie's botox shot on April 22.
July 9, 2026 11:05 AM EDT
FDA quietly stops releasing CRLs
The FDA has paused its public release of pharma rejection letters as the agency seeks to avoid litigation around releasing the often sensitive information.
The …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has…
Trump administration pushes the FDA to formalize its release of drug rejection letters via new rulemaking, with DTC ad and Phase…
The Supreme Court says it won’t wade into the pharma industry’s yearslong legal battle over Medicare drug price negotiations. The…
FDA will end its CMC Development and Readiness Pilot in April 2027 after low participation — only 21 of 27 expected drugmakers…
The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading…
The FDA is going forward with an investigation into the safet | The FDA is going forward with an investigation into the safety of…
